Skip to main content

Peer Review reports

From: Real-world evidence of switching P2Y12 receptor–inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry

Original Submission
13 May 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
11 Jun 2022 Reviewed Reviewer Report
3 Oct 2022 Reviewed Reviewer Report - Stefano De Servi
14 Nov 2022 Author responded Author comments - Hyo-Soo Kim
Resubmission - Version 3
14 Nov 2022 Submitted Manuscript version 3
25 Nov 2022 Author responded Author comments - Hyo-Soo Kim
Resubmission - Version 4
25 Nov 2022 Submitted Manuscript version 4
29 Nov 2022 Author responded Author comments - Hyo-Soo Kim
Resubmission - Version 5
29 Nov 2022 Submitted Manuscript version 5
5 Dec 2022 Author responded Author comments - Hyo-Soo Kim
Resubmission - Version 6
5 Dec 2022 Submitted Manuscript version 6
14 Dec 2022 Author responded Author comments - Hyo-Soo Kim
Resubmission - Version 7
14 Dec 2022 Submitted Manuscript version 7
28 Dec 2022 Reviewed Reviewer Report
28 Dec 2022 Reviewed Reviewer Report - Stefano De Servi
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
29 Dec 2022 Editorially accepted
9 Jan 2023 Article published 10.1186/s12872-022-03034-5

You can find further information about peer review here.

Back to article page